Giant Axonal Neuropathy Market Size and Share Analysis, Growth Opportunities, Challenges, Key Companies, Treatment Algorithm, Emerging Pipeline Therapies, and Epidemiology Forecasted

Delveinsight Business Research LLP
DelveInsight’s “Giant Axonal Neuropathy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Giant Axonal Neuropathy Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Giant Axonal Neuropathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Giant Axonal Neuropathy: An Overview

Giant axonal neuropathy (GAN) is a rare inherited genetic disorder that severely affects the peripheral as well as the central nervous system. GAN is characterized by abnormally large and dysfunctional axons called giant axons. The onset of GAN ranges from early infancy to late childhood

Treatment of Giant Axonal Neuropathy is symptomatic and supportive in nature and often encompasses multiple teams of medical professionals Services for visually and/or mobility impaired people may be of help to people with GAN.

Giant Axonal Neuropathy Market Key Facts

As per the Orphanet (2021), the prevalence of GAN is unknown, but to date, approximately 50 families have been reported. The frequency of this disease, however, is likely to be underestimated, due to patients with incomplete phenotypes and a high level of consanguinity among some populations. It occurs equally in both sexes.

Laguna et al. (2020), in a multicenter observational retrospective study, recorded French patients with GAN mutations, and 10 patients were identified. The mean age of patients was 9.7 years (2–18), and all patients met infant developmental milestones and had a family history of consanguinity.

According to National Organization for Rare Disorders (NORD), the risk for GAN is the same for males and females.

Giant Axonal Neuropathy Market

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Giant Axonal Neuropathy market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Giant Axonal Neuropathy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Get the PDF Sample of the Report:-

Giant Axonal Neuropathy Epidemiology

The epidemiology section covers insights about the historical and current Giant Axonal Neuropathy patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Giant Axonal Neuropathy (GAN) Epidemiology Segmentation

Total Prevalent of Cases of Giant axonal neuropathy 

Total Diagnosed Prevalent cases of Giant axonal neuropathy 

Total Treatable cases of Giant axonal neuropathy

Giant Axonal Neuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Giant Axonal Neuropathy market or expected to get launched in the market during the study period. The analysis covers Giant Axonal Neuropathy market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Giant Axonal Neuropathy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Giant Axonal Neuropathy Therapeutics Analysis

Globally, only a limited number of companies are involved in the development of novel treatment options for Giant Axonal Neuropathy. This might be due to the difficulty in studying GAN, given its inherent heterogeneity and challenges related to the evaluation of ablation, and may be due to its extremely rare nature. However, the dynamics of the GAN market might change in the coming years.

At present, Taysha Gene Therapies is involved in the development of a pharmaceutical agent for this rare Disorder.

Taysha Gene Therapies is currently evaluating TSHA-120 (Phase I/II), an intrathecally dosed AAV9 gene therapy currently being evaluated in a clinical trial for the treatment of GAN. The trial is being conducted by the National Institutes of Health (NIH) in close collaboration with a leading patient advocacy group (Hannah’s Hope) focused on finding treatments and cures for GAN.

Get More Detailed Insights into the Emerging Therapies & Key Companies:-

Table of Content

1. Key Insights

2. Executive Summary 

3. Giant Axonal Neuropathy Competitive Intelligence Analysis

4. Giant Axonal Neuropathy Market Overview at a Glance

5. Giant Axonal Neuropathy Disease Background and Overview

6. Giant Axonal Neuropathy Patient Journey

7. Giant Axonal Neuropathy Epidemiology and Patient Population

8. Giant Axonal Neuropathy Treatment Algorithm, Current Treatment, and Medical Practices

9. Giant Axonal Neuropathy Unmet Needs

10. Key Endpoints of Giant Axonal Neuropathy Treatment

11. Giant Axonal Neuropathy Marketed Products

12. Giant Axonal Neuropathy Emerging Therapies

13. Giant Axonal Neuropathy Seven Major Market Analysis

14. Attribute Analysis

15. Giant Axonal Neuropathy Market Outlook (7 major markets)

16. Giant Axonal Neuropathy Access and Reimbursement Overview

17. KOL Views on the Giant Axonal Neuropathy Market.

18. Giant Axonal Neuropathy Market Drivers

19. Giant Axonal Neuropathy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:-

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: